Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gallium Maltolate in Relapsed Glioblastoma
NCT04319276Phase 1Active, not recruiting
- Sponsor
- Medical College of Wisconsin
- Start
- Nov 2022
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of gallium maltolate in glioblastoma (GBM) (6 cohorts), sponsored by Medical College of Wisconsin. Primary endpoint: Maximum-tolerated dose at 28 days. Started Nov 2022; status: active, not recruiting.
02
Drugs
gallium maltolate
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT04319276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04319276.